Anti-CD40 antibodies and methods of treating cancer having CD40+ tumor cells

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 10640567
APP PUB NO 20170240642A1
SERIAL NO

15588919

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to antibodies (and fragments, variants, fusions and derivatives thereof) with multivalent binding specificity for CD40, which have a potency for dendritic cell activation which is higher than, or is equal to, the potency for B cell activation and wherein the antibody, antigen-binding fragment, or fusion, variant or derivative thereof has an affinity (KD) for CD40 of less than 1×10−10 M, which have utility in the treatment of diseases such as cancer. The invention also relates to pharmaceutical compositions, uses, methods and kits comprising such antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ALLIGATOR BIOSCIENCE ABMEDICON VILLAGE LUND SE-223 81

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Dahlen, Eva Maria Arlov, SE 2 8
Ellmark, Peter Bo Joakim Lund, SE 3 19

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 5, 2027
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 5, 2031
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00